| # | Title | Journal | Year | Citations |
|---|
| 1 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma | Leukemia | 2008 | 787 |
| 2 | Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2015 | 458 |
| 3 | Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus | Leukemia | 2007 | 349 |
| 4 | Psychiatric Morbidity and Impact on Hospital Length of Stay Among Hematologic Cancer Patients Receiving Stem-Cell Transplantation | Journal of Clinical Oncology | 2002 | 279 |
| 5 | Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2021 | 265 |
| 6 | Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients | Blood | 2011 | 259 |
| 7 | Management of treatment-emergent peripheral neuropathy in multiple myeloma | Leukemia | 2012 | 217 |
| 8 | Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species | Blood | 2001 | 184 |
| 9 | Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure | Blood | 2008 | 164 |
| 10 | Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study | Blood | 2011 | 161 |
| 11 | Role of Depression As a Predictor of Mortality Among Cancer Patients After Stem-Cell Transplantation | Journal of Clinical Oncology | 2005 | 156 |
| 12 | Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clínic of Barcelona experience | Blood | 2009 | 132 |
| 13 | Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia | Blood | 2006 | 130 |
| 14 | Bortezomib: an effective agent in extramedullary disease in multiple myeloma | European Journal of Haematology | 2006 | 129 |
| 15 | Veno-occlusive disease of the liver after hemopoietic cell transplantation | European Journal of Haematology | 2000 | 124 |
| 16 | The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings | Blood | 2001 | 118 |
| 17 | New prognostic markers in chronic lymphocytic leukemia | Blood Reviews | 2008 | 118 |
| 18 | Chronic lymphocytic leukemia and autoimmunity: a systematic review | Haematologica | 2011 | 117 |
| 19 | A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence | Leukemia | 2010 | 109 |
| 20 | Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling | Blood | 2013 | 107 |
| 21 | Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status | Leukemia | 2001 | 105 |
| 22 | Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations | Journal of Clinical Oncology | 2010 | 101 |
| 23 | Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia | Leukemia | 2002 | 100 |
| 24 | Extramedullary multiple myeloma escapes the effect of thalidomide | Haematologica | 2004 | 100 |
| 25 | Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL‐IPI | American Journal of Hematology | 2017 | 79 |
| 26 | Transplantation for multiple myeloma: who, when, how often? | Blood | 2003 | 76 |
| 27 | Monoclonal Gammopathy of Undetermined Significance: Predictors of Malignant Transformation and Recognition of an Evolving Type Characterized by a Progressive Increase in M Protein Size | Mayo Clinic Proceedings | 2007 | 76 |
| 28 | Patient-rated emotional and physical functioning among hematologic cancer patients during hospitalization for stem-cell transplantation | Bone Marrow Transplantation | 2005 | 75 |
| 29 | Allogeneic transplantation of CD34+selected cells from peripheral blood from human leukocyte antigen–identical siblings: detrimental effect of a high number of donor CD34+ cells? | Blood | 2001 | 71 |
| 30 | Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis | Blood | 2014 | 62 |
| 31 | Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect | Bone Marrow Transplantation | 2000 | 57 |
| 32 | Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model | Haematologica | 2014 | 56 |
| 33 | Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents | Cytokine | 2008 | 41 |
| 34 | Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia | Leukemia | 2002 | 34 |
| 35 | Treatment of Chronic Lymphocytic Leukemia: Achieving Minimal Residual Disease–Negative Status As a Goal | Journal of Clinical Oncology | 2005 | 34 |
| 36 | Life expectancy of young adults with follicular lymphoma | Annals of Oncology | 2015 | 31 |
| 37 | Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis | European Journal of Haematology | 2000 | 30 |
| 38 | Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration | European Journal of Haematology | 2006 | 30 |
| 39 | Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center | Cancer | 2018 | 30 |
| 40 | Thalidomide in refractory and relapsing multiple myeloma | Seminars in Oncology | 2001 | 29 |
| 41 | Chronic lymphocytic leukaemia: a short overview | Annals of Oncology | 2008 | 29 |
| 42 | Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival | European Journal of Haematology | 2001 | 26 |
| 43 | Survivin expression in the progression of chronic myeloid leukemia: A sequential study in 16 patients | Leukemia and Lymphoma | 2005 | 26 |
| 44 | Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia | Cytometry Part B - Clinical Cytometry | 2006 | 26 |
| 45 | New Hematologic Response Criteria Predict Survival in Patients With Immunoglobulin Light Chain Amyloidosis Treated With High-Dose Melphalan and Autologous Stem-Cell Transplantation | Journal of Clinical Oncology | 2013 | 26 |
| 46 | MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia | Leukemia and Lymphoma | 2013 | 26 |
| 47 | Clinical outcome in patients with intramedullary spinal cord metastases from lung cancer | Clinical and Translational Oncology | 2007 | 25 |
| 48 | Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation | Bone Marrow Transplantation | 2000 | 24 |
| 49 | Rituximab in chronic lymphocytic leukemia | Seminars in Oncology | 2003 | 24 |
| 50 | Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation | Biology of Blood and Marrow Transplantation | 2020 | 24 |
